SCROLL
Xeureka Inc. uses the latest computational technology,
including cutting-edge AI and simulations,
to improve the efficiency and success rate of drug discovery research.
Ultimately, we aim to contribute to the swift,
economical delivery of effective medicines to patients suffering from disease.
TECHNOLOGY
In addition to analysis and screening services, we plan to sell software and provide SaaS in the future.
Please contact us to discuss how we can customize a solution to meet your needs, including the establishment of a computing environment.
-
Target Analysis
- AI generation and analysis of multiple putative target structures
- Enhancement of low-resolution structural data
READ MORE
-
Ultra Large Scale Virtual Screening
- Construction of ultra-large scale and AI-generated virtual libraries.
- Virtual Screening approach designed to fit customer needs using SBVS or LBVS.
- Low-cost, large-scale Virtual Screening
READ MORE
-
Large Scale Binding Free Energy Calculation
- Absolute binding free energy calculation
- High-speed quantum chemical calculations
READ MORE
PARTNERSHIP
Xeureka provides solutions for drug discovery research in the areas of both the Dry (computational) and Wet (experimental) drug discovery.
We will develop further value-added services in collaboration with external partners that can provide significant experimental technology capabilities.
NEWS / BLOG
-
2024.02 01
NEWS
Mitsui & Co. Subsidiary, Xeureka, Launches Tokyo-1 Project Propelling AI-Driven Drug DiscoveryREAD MORE
-
2024.01 16
BLOG
【Case study】Ultra Large Scale Virtual ScreeningREAD MORE
-
2023.05 31
NEWS
Xeureka Accelerates AI Drug Discovery with Cutting-edge Supercomputer Powered by NVIDIA, Launches Tokyo-1 Project for Leading Pharmaceutical Companies in JapanREAD MORE